<SEC-DOCUMENT>0001104659-25-050435.txt : 20250519
<SEC-HEADER>0001104659-25-050435.hdr.sgml : 20250519
<ACCEPTANCE-DATETIME>20250519160520
ACCESSION NUMBER:		0001104659-25-050435
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250515
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250519
DATE AS OF CHANGE:		20250519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COLLEGIUM PHARMACEUTICAL, INC
		CENTRAL INDEX KEY:			0001267565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37372
		FILM NUMBER:		25963867

	BUSINESS ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072
		BUSINESS PHONE:		781-713-3699

	MAIL ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COLLEGIUM PHARMACEUTICAL INC
		DATE OF NAME CHANGE:	20031020
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2515549d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:coll="http://collegiumpharma.com/20250515">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_coll_collegiumpharma.com_20250515 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20250515_20250515 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001267565 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000004" name="dei:EntityCentralIndexKey">0001267565</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="coll-20250515.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-05-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-15</xbrli:startDate>
        <xbrli:endDate>2025-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_902_edei--DocumentType_c20250515__20250515_z2lLdAz9jGY5"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <b><span id="xdx_908_edei--DocumentPeriodEndDate_c20250515__20250515_zRd8lNkWJrTk"><ix:nonNumeric contextRef="AsOf2025-05-15" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May 15, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20250515__20250515_zTzjGhM3KWmg"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000011" name="dei:EntityRegistrantName">COLLEGIUM PHARMACEUTICAL, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20250515__20250515_zkMQXXOvYP35"><ix:nonNumeric contextRef="AsOf2025-05-15" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Virginia</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityFileNumber_c20250515__20250515_zq154dJmWoFc"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000013" name="dei:EntityFileNumber">001-37372</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20250515__20250515_zvs1tXI3m4e3"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000014" name="dei:EntityTaxIdentificationNumber">03-0416362</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or Other
    Jurisdiction<br/>
 of Incorporation or Organization)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(IRS Employer Identification<br/>
 No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: center; width: 100%"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20250515__20250515_ztk32uuhfeVg"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000015" name="dei:EntityAddressAddressLine1">100 Technology Center Drive</ix:nonNumeric></span></b></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td style="text-align: center"><b><span id="xdx_907_edei--EntityAddressAddressLine2_c20250515__20250515_zHSLbpI0XsFk"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span></b></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20250515__20250515_z5pLs7Spgz0c"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000017" name="dei:EntityAddressCityOrTown">Stoughton</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20250515__20250515_z1XxGF90ZE7c"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span></b> <b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20250515__20250515_zBB9WqmQELa1"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000019" name="dei:EntityAddressPostalZipCode">02072</ix:nonNumeric></span></b></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: center">(Address of principal executive offices) (Zip Code)</td></tr>
     </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90F_edei--CityAreaCode_c20250515__20250515_z6jyuqgLMEr4"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000020" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_90A_edei--LocalPhoneNumber_c20250515__20250515_z2S43ODXTYYa"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000021" name="dei:LocalPhoneNumber">713-3699</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of
    each class</b></span></td>
    <td style="vertical-align: bottom; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each
    exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--Security12bTitle_c20250515__20250515_zAUfSP3XqCT8"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000022" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="padding: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--TradingSymbol_c20250515__20250515_zP1UDygbJ3Nd"><ix:nonNumeric contextRef="AsOf2025-05-15" id="Fact000023" name="dei:TradingSymbol">COLL</ix:nonNumeric></span></span></td>
    <td style="padding: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--SecurityExchangeName_c20250515__20250515_z6ihnPR7tEL2"><ix:nonNumeric contextRef="AsOf2025-05-15" format="ixt-sec:exchnameen" id="Fact000024" name="dei:SecurityExchangeName">The NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration: underline">see</span> General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_903_edei--WrittenCommunications_c20250515__20250515_z7P3nqoEbaQh"><ix:nonNumeric contextRef="AsOf2025-05-15" format="ixt:booleanfalse" id="Fact000025" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span>&#160;
Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Wingdings"><span id="xdx_901_edei--SolicitingMaterial_c20250515__20250515_z4WDD70P7z2l"><ix:nonNumeric contextRef="AsOf2025-05-15" format="ixt:booleanfalse" id="Fact000026" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;
Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20250515__20250515_zvhcDB6zvYV9"><ix:nonNumeric contextRef="AsOf2025-05-15" format="ixt:booleanfalse" id="Fact000027" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160; Pre-commencement communications
pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20250515__20250515_zOUrY4DKn0U5"><ix:nonNumeric contextRef="AsOf2025-05-15" format="ixt:booleanfalse" id="Fact000028" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;
Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20250515__20250515_z0nxKB6bQVK9" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-05-15" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;<span style="font-family: Wingdings">&#168;</span></span></p>








<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span style="font-size: 10pt"><b>Item 5.02</b></span></td>
    <td style="text-align: justify; width: 90%; font-size: 10pt"><span style="font-size: 10pt"><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On May 15, 2025, Collegium Pharmaceutical, Inc. (the &#8220;Company&#8221;)
held its 2025 Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;), at which the Company&#8217;s shareholders approved the
Company&#8217;s&#160;2025 Equity Incentive Plan&#160;(the &#8220;Plan&#8221;), which provides for the grant of stock-based awards to officers,
directors and employees of the Company. A description of the material terms of the Plan is contained in the Company&#8217;s Definitive
Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on March 28, 2025 (the &#8220;Proxy Statement&#8221;).
The description of the Plan is qualified in its entirety by reference to the plan document attached hereto as Exhibit 10.1, which is incorporated
by reference into this Item 5.02.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
  <td style="width: 10%"><b>Item 5.07</b></td>
  <td style="width: 90%"><b>Submission of Matters to a Vote of Security Holders.</b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">A total of 32,131,798 shares of common stock of <span style="background-color: white">the
Company</span> were entitled to vote as of March 25, 2025, the record date for the Annual Meeting, of which 29,094,522 were present in
person or by proxy at the Annual Meeting.&#160; The following is a summary of the final voting results for each matter presented to shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PROPOSAL 1</b>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Election of eight Directors to hold office until the 2026 Annual Meeting
of Shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Nominee</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Against</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Abstentions</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker&#160;Non-Votes</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-size: 10pt; text-align: left">Rita Balice-Gordon</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 15%; font-size: 10pt; text-align: center">24,842,387</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 15%; font-size: 10pt; text-align: center">251,845</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 15%; font-size: 10pt; text-align: center">2,550,989</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 15%; font-size: 10pt; text-align: center">1,449,301</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Garen Bohlin</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">24,980,953</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">127,522</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2,536,746</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">1,449,301</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">John Fallon</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">24,314,536</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">793,400</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2,537,285</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">1,449,301</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">John Freund</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">24,494,346</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">614,373</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2,536,502</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">1,449,301</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Vikram Karnani</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">25,001,176</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">107,410</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2,536,635</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">1,449,301</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Nancy Lurker</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">25,089,514</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">18,982</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2,536,725</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">1,449,301</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Carlos Paya</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">25,074,339</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">21,938</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2,548,944</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">1,449,301</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Gino Santini</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">24,829,920</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">278,655</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2,536,646</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">1,449,301</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of Rita Balice-Gordon, Garen Bohlin, John Fallon, John Freund,
Vikram Karnani, Nancy Lurker, Carlos Paya and Gino Santini was elected by the Company&#8217;s shareholders as Directors to hold office
until the 2026 Annual Meeting of Shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PROPOSAL 2:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approval of, on an advisory basis, the compensation of the Company&#8217;s
named executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Against</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Abstentions</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker&#160;Non-Votes</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; font-size: 10pt; text-align: center">22,867,414</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">2,233,541</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">2,544,266</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">1,449,301</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On an advisory basis, the Company&#8217;s shareholders approved the
compensation of the Company&#8217;s named executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PROPOSAL 3:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Approval of, on an advisory basis, the preferred frequency of shareholder
advisory votes on the compensation of the Company&#8217;s named executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">1 Year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2 Years</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">3 Years</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Abstentions</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker&#160;Non-Votes</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt; text-align: center">26,389,740</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center">5,042</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center">961,581</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center">288,858</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center">1,449,301</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On an advisory basis, the Company&#8217;s shareholders indicated a
preferred frequency of shareholder advisory votes on the compensation of the Company&#8217;s named executive officers of every one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PROPOSAL 4</b>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Ratification of the appointment of Deloitte&#160;&amp; Touche LLP as
the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Against</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Abstentions</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker&#160;Non-Votes</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; font-size: 10pt; text-align: center">28,706,712</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">141,452</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">246,358</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">0</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proposal 4 was approved by the Company&#8217;s shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PROPOSAL 5</b>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approval of the Collegium Pharmaceutical, Inc. 2025 Equity Incentive
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Against</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Abstentions</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker&#160;Non-Votes</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; font-size: 10pt; text-align: center">20,255,783</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">7,143,482</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">245,956</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: center">1,449,301</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Plan was approved by the Company&#8217;s shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 10%"><b>Item 9.01. </b></td>
  <td style="width: 90%"><b>Financial Statements and Exhibits.</b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Exhibits.</b>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr>
    <td style="width: 8%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="width: 90%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm2515549d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2515549d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded in the cover page formatted in Inline XBRL)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May&#160;19, 2025</span></td>
    <td colspan="2"><span style="font-size: 10pt">Collegium Pharmaceutical,&#160;Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Colleen Tupper</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name: Colleen Tupper</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title: Executive Vice President and Chief Financial Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZi42huujSUkWsIqWI22CnEmwzZRL/juQtjS3iMDAM733vCTERa1qZFhlOy7KACru+1R6hxAYZ7RmDI9tsUwi3xItxnrX1w/sDMwoMBmY+VUoHYbDejcM6BZnEahGrBKRKZQKHnYi+eka2MTVab3QL2tZwYOrZoNf8GhMq/SRL3WuoOiI7QzaF2VSO8huUnCnY010/iK8OiiIT0WSYSKyZbn1w5U+P9ktC3mIX6txI/zf6AAUaSoo= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2515549d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20</B></FONT><B><FONT STYLE="font-size: 10pt">25
EQUITY INCENTIVE PLAN</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;1. <FONT STYLE="text-transform: uppercase"><U>GENERAL
PURPOSE OF THE PLAN; DEFINITIONS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of the plan is the
Collegium Pharmaceutical,&nbsp;Inc. 2025 Equity Incentive Plan (the &ldquo;Plan&rdquo;). The purpose of the Plan is to encourage and enable
the officers, employees, Non-Employee Directors and Consultants of Collegium Pharmaceutical,&nbsp;Inc. (the &ldquo;Company&rdquo;) and
its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire
a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&rsquo;s welfare
will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts
on the Company&rsquo;s behalf and strengthening their desire to remain with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following terms shall
be defined as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Act&rdquo;</I></FONT>
means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Administrator&rdquo;</I></FONT>
means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation
committee and which is comprised of not less than two Non-Employee Directors who are independent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<I>Affiliate</I>&rdquo;
means, at the time of determination, any &ldquo;parent&rdquo; or &ldquo;subsidiary&rdquo; of the Company as such terms are defined in
Rule&nbsp;405 of the Act. The Board will have the authority to determine the time or times at which &ldquo;parent&rdquo; or &ldquo;subsidiary&rdquo;
status is determined within the foregoing definition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Award&rdquo;</I></FONT>
or <I>&ldquo;Awards,&rdquo;</I> except where referring to a particular category of grant under the Plan, shall include Incentive Stock
Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards,
Cash-Based Awards and Dividend Equivalent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Award
Agreement&rdquo;</I></FONT> means a written or electronic document setting forth the terms and provisions applicable to an Award granted
under the Plan. Each Award Agreement is subject to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Board&rdquo;</I></FONT>
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Cash-Based
Award&rdquo;</I></FONT> means an Award entitling the recipient to receive a cash-denominated payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Code&rdquo;</I></FONT>
means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Consultant&rdquo;</I></FONT>
means a consultant or adviser who provides <I>bona fide</I> services to the Company or an Affiliate as an independent contractor and who
qualifies as a consultant or advisor under Instruction A.1.(a)(1)&nbsp;of Form&nbsp;S-8 under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Dividend
Equivalent Right&rdquo;</I></FONT> means an Award entitling the grantee to receive credits based on cash dividends that would have been
paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued
to and held by the grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Effective
Date&rdquo;</I></FONT> means the date on which the Plan becomes effective as set forth in Section&nbsp;19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Exchange
Act&rdquo;</I></FONT> means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Fair
Market Value&rdquo;</I></FONT> of the Stock on any given date means the fair market value of the Stock determined in good faith by the
Administrator; provided, however, that if the Stock is listed on the National Association of Securities Dealers Automated Quotation System
(&ldquo;Nasdaq&rdquo;), Nasdaq Global Market, The New York Stock Exchange or another national securities exchange or traded on any established
market, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination
shall be made by reference to the last date preceding such date for which there are market quotations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Incentive
Stock Option&rdquo;</I></FONT> means any Stock Option designated and qualified as an &ldquo;incentive stock option&rdquo; as defined in
Section&nbsp;422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Minimum
Vesting Period&rdquo; </I></FONT>means the one-year period following the date of grant of an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Non-Employee
Director&rdquo;</I></FONT> means a member of the Board who is not also an employee of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Non-Qualified
Stock Option&rdquo;</I></FONT> means any Stock Option that is not an Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Option&rdquo;</I></FONT>
or <I>&ldquo;Stock Option&rdquo;</I> means any option to purchase shares of Stock granted pursuant to Section&nbsp;5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Restricted
Shares&rdquo;</I></FONT> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or
the Company&rsquo;s right of repurchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Restricted
Stock Award&rdquo;</I></FONT> means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may
determine at the time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Restricted
Stock Units&rdquo;</I></FONT> means an Award of stock units subject to such restrictions and conditions as the Administrator may determine
at the time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Sale
Event&rdquo;</I></FONT> shall mean (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis
to an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&rsquo;s
outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power
and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately
upon completion of such transaction, (iii)&nbsp;the sale of all of the Stock of the Company to an unrelated person, entity or group thereof
acting in concert or (iv)&nbsp;any other transaction in which the owners of the Company&rsquo;s outstanding voting power immediately prior
to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately
upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<I>Sale Price</I>&rdquo;
means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share
of Stock pursuant to a Sale Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Section&nbsp;409A&rdquo;</I></FONT>
means Section&nbsp;409A of the Code and the regulations and other guidance promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Service
Relationship&rdquo; </I></FONT>means any relationship as an employee, director or Consultant of the Company or any Affiliate (e.g., a
Service Relationship shall be deemed to continue without interruption in the event an individual&rsquo;s status changes from full-time
employee to part-time employee or Consultant).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Stock&rdquo;</I></FONT>
means the Common Stock, par value $0.001 per share, of the Company, subject to adjustments pursuant to Section&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Stock
Appreciation Right&rdquo;</I></FONT> means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly
provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value of the Stock on the date of
exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the
Stock Appreciation Right shall have been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Subsidiary&rdquo;</I></FONT>
means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly
or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Ten
Percent Owner&rdquo;</I></FONT> means an employee who owns or is deemed to own (by reason of the attribution rules&nbsp;of Section&nbsp;424(d)&nbsp;of
the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Unrestricted
Stock Award&rdquo;</I></FONT> means an Award of shares of Stock free of any restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;2. <FONT STYLE="text-transform: uppercase"><U>ADMINISTRATION
OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Administration
of Plan</U>. The Plan shall be administered by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Powers
of Administrator</U>. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including
the power and authority:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
select the individuals to whom Awards may from time to time be granted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation
Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards and Dividend Equivalent Rights,
or any combination of the foregoing, granted to any one or more grantees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
determine the number of shares of Stock to be covered by any Award;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan,
of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
accelerate at any time the exercisability or vesting of all or any portion of any Award;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;subject
to the provisions of Section&nbsp;5(c), to extend at any time the period in which Stock Options may be exercised; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;at
any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings
as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to
make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan;
and to otherwise supervise the administration of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All decisions and interpretations
of the Administrator shall be binding on all persons, including the Company and Plan grantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delegation
of Authority to Grant Awards</U>. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting
of one or more officers of the Company all or part of the Administrator&rsquo;s authority and duties with respect to the granting of Awards
to individuals who are (i)&nbsp;not subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and (ii)&nbsp;not
members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying
Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price
and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time, but such action shall not invalidate
any prior actions of the Administrator&rsquo;s delegate or delegates that were consistent with the terms of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Award
Agreement</U>. Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations for each
Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification</U>.
Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation,
construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and
any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss,
damage or expense (including, without limitation, reasonable attorneys&rsquo; fees) arising or resulting therefrom to the fullest extent
permitted by law and/or under the Company&rsquo;s articles or bylaws or any directors&rsquo; and officers&rsquo; liability insurance coverage
which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-U.S.
Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in
which the Company and its Affiliates operate or have employees or other individuals eligible for Awards, the Administrator, in its sole
discretion, shall have the power and authority to: (i)&nbsp;determine which Affiliates shall be covered by the Plan; (ii)&nbsp;determine
which individuals outside the United States are eligible to participate in the Plan; (iii)&nbsp;modify the terms and conditions of any
Award granted to individuals outside the United States to comply with applicable laws; (iv)&nbsp;establish subplans and modify exercise
procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such
subplans and/or modifications shall be incorporated into and made part of this Plan); provided, however, that no such subplans and/or
modifications shall increase the share limitations contained in Section&nbsp;3(a)&nbsp;hereof; and (v)&nbsp;take any action, before or
after an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental
regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards
shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable
United States governing statute or law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Minimum
Vesting Period</U>. The vesting period for each Award granted under the Plan must be at least equal to the Minimum Vesting Period; provided,
however, nothing in this Section&nbsp;2(g)&nbsp;shall limit the Administrator&rsquo;s authority to accelerate the vesting of Awards as
set forth in Section&nbsp;2(b)(v)&nbsp;above; and, provided further, notwithstanding the foregoing, (1)&nbsp;up to 5% of the shares of
Stock authorized for issuance under the Plan may be utilized for Unrestricted Stock Awards or other Awards with a vesting period that
is less than the Minimum Vesting Period and (2)&nbsp;annual Awards to Non-Employee Directors that occur in connection with the Company&rsquo;s
annual meeting of stockholders may vest on the date of the Company&rsquo;s next annual meeting of stockholders, provided that the vesting
period is at least fifty (50) weeks from the date of grant (each such Award, an &ldquo;Excepted Award&rdquo;). Notwithstanding the foregoing,
in addition to Excepted Awards, the Administrator may grant Awards that vest (or permit previously granted Awards to vest) within the
Minimum Vesting Period (i)&nbsp;if such Awards are granted as substitute Awards in replacement of other Awards (or awards previously granted
by an entity being acquired (or assets of which are being acquired)) that were scheduled to vest within the Minimum Vesting Period or
(ii)&nbsp;if such Awards are being granted in connection with an elective deferral of cash compensation that, absent a deferral election,
otherwise would have been paid to the grantee within the Minimum Vesting Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;3. <FONT STYLE="text-transform: uppercase"><U>STOCK
ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock
Issuable</U>. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be equal to 3,474,404 shares,
reduced by one share for each share of Stock granted under the Company&rsquo;s Amended and Restated 2014 Stock Incentive Plan after March&nbsp;25,
2025) , subject to adjustment as provided in this Section&nbsp;3. For purposes of this limitation, the shares of Stock underlying any
awards under the Plan and under the Company&rsquo;s Amended and Restated 2014 Stock Incentive Plan that are forfeited, canceled or otherwise
terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan and, to the extent
permitted under Section&nbsp;422 of the Code and the regulations promulgated thereunder, the shares of Stock that may be issued as Incentive
Stock Options. Notwithstanding the foregoing, the following shares shall not be added to the shares authorized for grant under the Plan:
(i)&nbsp;shares tendered or held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding
and (ii)&nbsp;shares subject to a Stock Appreciation Right that are not issued in connection with the stock settlement of the Stock Appreciation
Right upon exercise thereof. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to
the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such
maximum number pursuant to any type or types of Award; provided, however, that no more than 10,000,000 shares of the Stock may be issued
in the form of Incentive Stock Options. The shares available for issuance under the Plan may be authorized but unissued shares of Stock
or shares of Stock reacquired by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Changes
in Stock</U>. Subject to Section&nbsp;3(c)&nbsp;hereof, if, as a result of any reorganization, recapitalization, reclassification, stock
dividend, stock split, reverse stock split or other similar change in the Company&rsquo;s capital stock, the outstanding shares of Stock
are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional
shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares
of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the
Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent
or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i)&nbsp;the maximum number of shares
reserved for issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options,
(ii)&nbsp;the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii)&nbsp;the repurchase
price, if any, per share subject to each outstanding Restricted Stock Award and (iv)&nbsp;the exercise price for each share subject to
any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e.,
the exercise price multiplied by the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options
and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number
of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends
paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final,
binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator
in its discretion, may make a cash payment in lieu of fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mergers
and Other Transactions</U>. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption
or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor
entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise
prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution
of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case,
except as may be otherwise provided in the relevant Award Agreement, all Options and Stock Appreciation Rights with time-based vesting
conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become
fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions
shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions
relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator&rsquo;s
discretion or to the extent specified in the relevant Award Agreement. In the event of such termination, (i)&nbsp;the Company shall have
the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation
Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A)&nbsp;the Sale Price multiplied by the
number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in
excess of the Sale Price) and (B)&nbsp;the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided
that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option
or Stock Appreciation Right shall be cancelled for no consideration); or (ii)&nbsp;each grantee shall be permitted, within a specified
period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and
Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion)
to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied
by the number of vested shares of Stock under such Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Maximum
Awards to Non-Employee Directors</U>. Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded under this
Plan and all other cash compensation paid by the Company to any Non-Employee Director in any calendar year shall not exceed $750,000;
provided, however, that in the first calendar year in which an individual becomes a Non-Employee Director, the aggregate value of all
Awards awarded under this Plan and all other cash compensation paid by the Company to such Non-Employee Director for services as a Non-Employee
Director shall not exceed $1,000,000. For the purpose of this limitation, the value of any Award shall be its grant date fair value, as
determined in accordance with ASC 718 or successor provision but excluding the impact of estimated forfeitures related to service-based
vesting provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;4. <FONT STYLE="text-transform: uppercase"><U>ELIGIBILITY</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Grantees under the Plan will
be such employees, Non-Employee Directors or Consultants of the Company and its Affiliates as are selected from time to time by the Administrator
in its sole discretion; provided that Awards may not be granted to employees, Directors or Consultants who are providing services only
to any &ldquo;parent&rdquo; of the Company, as such term is defined in Rule&nbsp;405 of the Act, unless (i)&nbsp;the stock underlying
the Awards is treated as &ldquo;service recipient stock&rdquo; under Section&nbsp;409A or (ii)&nbsp;the Company has determined that such
Awards are exempt from or otherwise comply with Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;5. <FONT STYLE="text-transform: uppercase"><U>STOCK
OPTIONS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Award
of Stock Options</U>. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be in such
form as the Administrator may from time to time approve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock Options granted under
the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees
of the Company or any Subsidiary that is a &ldquo;subsidiary corporation&rdquo; within the meaning of Section&nbsp;424(f)&nbsp;of the
Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock Options granted pursuant
to this Section&nbsp;5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions,
not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options
may be granted in lieu of cash compensation at the optionee&rsquo;s election, subject to such terms and conditions as the Administrator
may establish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
Price</U>. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section&nbsp;5 shall be determined
by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. In the
case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not
less than 110 percent of the Fair Market Value on the grant date. Notwithstanding the foregoing, Stock Options may be granted with an
exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant (i)&nbsp;pursuant to a transaction
described in, and in a manner consistent with, Section&nbsp;424(a)&nbsp;of the Code, (ii)&nbsp;to individuals who are not subject to U.S.
income tax on the date of grant or (iii)&nbsp;the Stock Option is otherwise compliant with Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Option
Term</U>. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years
after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term
of such Stock Option shall be no more than five years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercisability;
Rights of a Stockholder</U>. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be
determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or
any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a
Stock Option and not as to unexercised Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Method
of Exercise</U>. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company,
specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except
to the extent otherwise provided in the Award Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
cash, by certified or bank check or other instrument acceptable to the Administrator;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Through
the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not
then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly
deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee
chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements
of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to Stock Options that are not Incentive Stock Options, by a &ldquo;net exercise&rdquo; arrangement pursuant to which the Company
will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does
not exceed the aggregate exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment instruments will be received subject to
collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased
pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance
with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements
contained in the Award Agreement or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company
is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned
shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock
Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a
third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response,
then the paperless exercise of Stock Options may be permitted through the use of such an automated system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Annual
Limit on Incentive Stock Options</U>. To the extent required for &ldquo;incentive stock option&rdquo; treatment under Section&nbsp;422
of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive
Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for
the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit,
it shall constitute a Non-Qualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;6. <FONT STYLE="text-transform: uppercase"><U>STOCK
APPRECIATION RIGHTS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Award
of Stock Appreciation Rights</U>. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is
an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Agreement)
having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the
Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been
exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
Price of Stock Appreciation Rights</U>. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair
Market Value of the Stock on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Grant
and Exercise of Stock Appreciation Rights</U>. Stock Appreciation Rights may be granted by the Administrator independently of any Stock
Option granted pursuant to Section&nbsp;5 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Terms
and Conditions of Stock Appreciation Rights</U>. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined
on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of
each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;7. <FONT STYLE="text-transform: uppercase"><U>RESTRICTED
STOCK AWARDS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Nature
of Restricted Stock Awards</U>. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award
of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may
be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Rights
as a Stockholder</U>. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have
the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that any dividends
paid by the Company with respect to any unvested Restricted Shares shall accrue and shall not be paid to the grantee unless and until
such Restricted Shares have vested. Unless the Administrator shall otherwise determine, (i)&nbsp;uncertificated Restricted Shares shall
be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until
such Restricted Shares are vested as provided in Section&nbsp;7(d)&nbsp;below, and (ii)&nbsp;certificated Restricted Shares shall remain
in the possession of the Company until such Restricted Shares are vested as provided in Section&nbsp;7(d)&nbsp;below, and the grantee
shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Restrictions</U>.
Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided
herein or in the Restricted Stock Award Agreement. Except as may otherwise be provided by the Administrator either in the Award Agreement
or, subject to Section&nbsp;16 below, in writing after the Award is issued, if a grantee&rsquo;s employment (or other Service Relationship)
with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination
shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed
to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&rsquo;s legal representative
simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership
of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that
are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vesting
of Restricted Shares</U>. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established
performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company&rsquo;s right
of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals,
objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed
&ldquo;vested.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;8. <FONT STYLE="text-transform: uppercase"><U>RESTRICTED
STOCK UNITS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Nature
of Restricted Stock Units</U>. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award
of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Agreement) upon the
satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service
Relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award shall
be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case
of Restricted Stock Units with a deferred settlement date that complies with Section&nbsp;409A, at the end of the vesting period, the
Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units with deferred settlement
dates are subject to Section&nbsp;409A and shall contain such additional terms and conditions as the Administrator shall determine in
its sole discretion in order to comply with the requirements of Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Election
to Receive Restricted Stock Units in Lieu of Compensation</U>. The Administrator may, in its sole discretion, permit a grantee to elect
to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any
such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and
in accordance with Section&nbsp;409A and such other rules&nbsp;and procedures established by the Administrator. Any such future cash compensation
that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock
on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The
Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such
limitations and other terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected
to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Rights
as a Stockholder</U>. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement
of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock
units underlying his Restricted Stock Units, subject to the provisions of Section&nbsp;11 and such terms and conditions as the Administrator
may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination</U>.
Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;16 below, in writing
after the Award is issued, a grantee&rsquo;s right in all Restricted Stock Units that have not vested shall automatically terminate upon
the grantee&rsquo;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;9. <FONT STYLE="text-transform: uppercase"><U>UNRESTRICTED
STOCK AWARDS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant
or Sale of Unrestricted Stock</U></FONT>. The Administrator may grant (or sell at par value or such higher purchase price determined by
the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may
receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services
or other valid consideration, or in lieu of cash compensation due to such grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;10. <FONT STYLE="text-transform: uppercase"><U>CASH-BASED
AWARDS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant
of Cash-Based Awards</U></FONT>. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles
the grantee to a payment in cash upon the attainment of specified performance goals. The Administrator shall determine the maximum duration
of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall
become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated
payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall
be made in accordance with the terms of the Award and may be made in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;11. <FONT STYLE="text-transform: uppercase"><U>DIVIDEND
EQUIVALENT RIGHTS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Dividend
Equivalent Rights</U>. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award
entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend
Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be
granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions
of Dividend Equivalent Rights shall be specified in the Award Agreement. Dividend equivalents credited to the holder of a Dividend Equivalent
Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents.
Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend
reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination
thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units
shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such
other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other
Award. For the avoidance of doubt, in no event shall any Dividend Equivalent Rights be paid unless or until such Award has vested. In
no event shall any Dividend Equivalent Rights be granted as a component of a Stock Option or Stock Appreciation Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination</U>.
Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;16 below, in writing
after the Award is issued, a grantee&rsquo;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&rsquo;s
termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;12. <FONT STYLE="text-transform: uppercase"><U>Transferability
of Awards</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transferability</U>.
Except as provided in Section&nbsp;12(b)&nbsp;below, during a grantee&rsquo;s lifetime, his or her Awards shall be exercisable only by
the grantee, or by the grantee&rsquo;s legal representative or guardian in the event of the grantee&rsquo;s incapacity. No Awards shall
be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution
or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind,
and any purported transfer in violation hereof shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Administrator
Action</U>. Notwithstanding Section&nbsp;12(a), the Administrator, in its discretion, may provide either in the Award Agreement regarding
a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Non-Qualified
Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such
family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms
and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Family
Member</U>. For purposes of Section&nbsp;12(b), &ldquo;family member&rdquo; shall mean a grantee&rsquo;s child, stepchild, grandchild,
parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee&rsquo;s household (other than a tenant
of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in
which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own
more than 50 percent of the voting interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Designation
of Beneficiary</U>. To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan may designate a
beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&rsquo;s death.
Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the
Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee,
the beneficiary shall be the grantee&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;13. <FONT STYLE="text-transform: uppercase"><U>TAX
WITHHOLDING</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payment
by Grantee</U>. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received
thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements
satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld
by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to
deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company&rsquo;s obligation to deliver evidence of
book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the
grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payment
in Stock</U>. The Administrator may require the Company&rsquo;s tax withholding obligation to be satisfied, in whole or in part, by the
Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as
of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does
not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes
of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible
in income of the grantees. The Administrator may also require the Company&rsquo;s tax withholding obligation to be satisfied, in whole
or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds
from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;14. <FONT STYLE="text-transform: uppercase"><U>Section&nbsp;409A
awards</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Awards are intended to be
exempt from Section&nbsp;409A to the greatest extent possible and to otherwise comply with Section&nbsp;409A. The Plan and all Awards
shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &ldquo;nonqualified deferred
compensation&rdquo; within the meaning of Section&nbsp;409A (a &ldquo;409A Award&rdquo;), the Award shall be subject to such additional
rules&nbsp;and requirements as specified by the Administrator from time to time in order to comply with Section&nbsp;409A. In this regard,
if any amount under a 409A Award is payable upon a &ldquo;separation from service&rdquo; (within the meaning of Section&nbsp;409A) to
a grantee who is then considered a &ldquo;specified employee&rdquo; (within the meaning of Section&nbsp;409A), then no such payment shall
be made prior to the date that is the earlier of (i)&nbsp;six months and one day after the grantee&rsquo;s separation from service, or
(ii)&nbsp;the grantee&rsquo;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest,
penalties and/or additional tax imposed pursuant to Section&nbsp;409A. Further, the settlement of any 409A Award may not be accelerated
except to the extent permitted by Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;15. <FONT STYLE="text-transform: uppercase"><U>TERMINATION
OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE,&nbsp;ETC.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
of Service Relationship</U>. If the grantee&rsquo;s Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate,
the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee&rsquo;s
right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was
granted or if the Administrator otherwise so provides in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;16. <FONT STYLE="text-transform: uppercase"><U>AMENDMENTS
AND TERMINATION</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board may, at any time,
amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying
changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding
Award without the holder&rsquo;s consent. Except as provided in Section&nbsp;3(b)&nbsp;or 3(c), without prior stockholder approval, in
no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation
Rights or effect repricing through cancellation and re-grants or cancellation of Stock Options or Stock Appreciation Rights in exchange
for cash or other Awards. To the extent required under the rules&nbsp;of any securities exchange or market system on which the Stock is
listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under
the Plan are qualified under Section&nbsp;422 of the Code, Plan amendments shall be subject to approval by Company stockholders. Nothing
in this Section&nbsp;16 shall limit the Administrator&rsquo;s authority to take any action permitted pursuant to Section&nbsp;3(b)&nbsp;or
3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;17. <FONT STYLE="text-transform: uppercase"><U>STATUS
OF PLAN</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the portion
of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall
have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in
connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements
to meet the Company&rsquo;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence
of such trusts or other arrangements is consistent with the foregoing sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;18. <FONT STYLE="text-transform: uppercase"><U>GENERAL
PROVISIONS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Distribution</U>. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company
in writing that such person is acquiring the shares without a view to distribution thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Issuance
of Stock</U>. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when
the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee,
at the grantee&rsquo;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when
the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by
United States mail, addressed to the grantee, at the grantee&rsquo;s last known address on file with the Company, notice of issuance and
recorded the issuance in its records (which may include electronic &ldquo;book entry&rdquo; records). Notwithstanding anything herein
to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of
Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to
the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable
laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed,
quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator
deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules&nbsp;and quotation
system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any
book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator
may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion,
deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right
to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including
a window-period limitation, as may be imposed in the discretion of the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stockholder
Rights</U>. Until Stock is deemed delivered in accordance with Section&nbsp;18(b), no right to vote or receive dividends or any other
rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise
of a Stock Option or any other action by the grantee with respect to an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Other
Compensation Arrangements; No Employment Rights</U>. Nothing contained in this Plan shall prevent the Board from adopting other or additional
compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases.
The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or
any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Trading
Policy Restrictions</U>. Option exercises and other Awards under the Plan shall be subject to the Company&rsquo;s insider trading policies
and procedures, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Clawback
Policy</U>. Awards under the Plan shall be subject to the Company&rsquo;s clawback policy, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;19. <FONT STYLE="text-transform: uppercase"><U>EFFECTIVE
DATE OF PLAN</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Plan shall become effective
upon stockholder approval in accordance with applicable state law, the Company&rsquo;s bylaws and articles of incorporation, and applicable
stock exchange rules. No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date
and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">SECTION&nbsp;20. <FONT STYLE="text-transform: uppercase"><U>GOVERNING
LAW</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Plan and all Awards and
actions taken thereunder shall be governed by, and construed in accordance with, the Commonwealth of Virginia, applied without regard
to conflict of law principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATE APPROVED BY BOARD OF DIRECTORS: March&nbsp;27,
2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATE APPROVED BY STOCKHOLDERS: May&nbsp;15, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>coll-20250515.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa+NebOdzZR+CYkxtmB5bTlKnysnKibwLiSBjzNGEbkI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:coll="http://collegiumpharma.com/20250515" elementFormDefault="qualified" targetNamespace="http://collegiumpharma.com/20250515">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://collegiumpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="coll-20250515_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="coll-20250515_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>coll-20250515_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>coll-20250515_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://collegiumpharma.com/role/Cover" xlink:href="coll-20250515.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://collegiumpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 15,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COLLEGIUM PHARMACEUTICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001267565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0416362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Technology Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Stoughton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">713-3699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COLL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2515549d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://collegiumpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>coll-20250515.xsd</File>
    <File>coll-20250515_lab.xml</File>
    <File>coll-20250515_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2515549d1_8k.htm">tm2515549d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2515549d1_8k.htm": {
   "nsprefix": "coll",
   "nsuri": "http://collegiumpharma.com/20250515",
   "dts": {
    "schema": {
     "local": [
      "coll-20250515.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "coll-20250515_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "coll-20250515_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2515549d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://collegiumpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2515549d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2515549d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-25-050435-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-050435-xbrl.zip
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MT%/XI@A0'!H?U#<*@3%4A.FR<Z3KUAYP;ZLMOG&_W!M9[9'_ 5!+ P04
M" "I@+-:6"H;L5@8   'H@  $@   '1M,C4Q-34T.60Q7SAK+FAT;>T]:W?:
MNK+?^16ZG+O/3M<VX ?OI)Q%@*3LO"@D;=,O60*+X,;8U#8!^NO/C&R##29
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M "$BFOHQ?D([CHA_0 H-F#3 8EHQQ CQ$N>$HU1HY)? 2@=A1;)*O#3CE2C
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M,LV/+D52;5.=X$^([?32?P%02P,$%     @ J8"S6HRW<>?@0P  (8@! !8
M  !T;3(U,34U-#ED,5]E>#$P+3$N:'1M[7UI<]M6%N5W5O$_8#(S75(5K'C-
M8F=215NTHQI;=DMR>O(1)!XEM$& P2*9_>OG;F\%0%&)E59H=57:(HGEK??=
MY=QS?_KE[-W;G\>CGWZ93@[AWPC_]]/9T=G;Z<\_?<O_PJ_?RL\_O7Q_^%MT
M>O;;V^G_^691%LWSZ-'#51.=94M51\?J*CHIETD1\Q=Q=*JJ;/$-W BW?M#W
M+9/J/"N>1P^_^?D?Q:Q>O?CIVP_!)8WZW#Q(\NP<+JNR\XOF1>3<]=/+GZ>?
M+[)9UL#;#Q[]].W+G[N/<*]__?[XS&WU@SK[C^*FVS;@13W/D5X^O:Z73@OA
MTH<O(K</<U4TJKJN)="O5^_?OIV^.?KX+OKPR^3DW>35]./9T:O)VYA;>73\
MZH"[N[FUU\Y)T-J[/4:+9)GEZ^?7/;MO/!\_=(?KY37=?/QL/)K^\^/1V6\1
MC/3T^.SHUVGTX>WDV/2\;Z7]X3$?6OU_\('T_X^RPA_6?[=UDRW6\F56I H?
M_@"N^^;GT^FKLZ/WQ]R.1P>1-SIT?5,E1;THJ^7SJ%VM5#5/:@4#^_'G-]/C
MZ<GD[7CTX>/)A_>GT^C]Z^CL%QZM%]'A]/71\1$^^_2G;S_>PG+]PD.WS9 ]
M/'B&8W9VH:(B6:JH7$0-_+W*DR+*:OQ[/'I5YKDZS]IE].$BJ9;)7+5--D]R
MO7V+^4'T^.'C9]'T]S9KUA%\ <_.+E7T 1^SAP_\1Y[^WI8O\(M_5/3G_D&$
M;UVUU:JLS8L_Z!>7D2KF95LEYRI*BA0^);,<&H,7E8M%-E<5=%LM5WFY5C@"
MQV7Q8"H?H\.L4O.FK&JZ]U59U&W>)$53XWNVZ8_;Z%?E<I44:]UN?.1XE,&S
M)M"./$L:F)%V51;1U07VY-]M>KZ$ 8BCK,@:^!E'@KJP@#77T*!&\LPHAPE3
M^3I*U4H5:0W;O:+?ZW8^5W6]:/-H7A9I.V^PY?C265MG!?R$0Y3,8<0K&)4D
M6E7EJLI4DU1K>"_('%4W\(?[LH/HJ,&QA7'(YMD*VIW"STF#]UYF:5:<XVLO
M(M@1-8Q8=)4U%U$2I3264=TDGU3PQ']4-0X)7*KR18(-N<KR/$KJNJV@S]$\
MAP&IH@S76@9S!F,!P\13G56FG?*JYL)9"'J <."PVW53SC]=E'E*\PY75&JV
MAF^S99O#8Z'M_$P9Y/&H[&_I3%TD^8(>6S>5*L[AHL+>GJH:NHMC6ZEE KV5
MEME!W)G]OH!M4%Y1UU6UA!&&@<G'HYF"05C $DMA'J-:-;@F80QF"JY^OA.]
M_X*'\='/(B0F\T8$Q$_?'NFS83Q:*CAJ:/V<JGE;@3R YT]X-S_Z\<F3& <9
M!"\T,(UI5>*U59NKFL<'OZK4.2WRDA]5J18NKW9C)=[*7*1+$+VPO1,X H9G
M164XF#3@+\ND2B.1O7/8Z:JH65C!AV76-,H()G-I$M49M#2IG&M =*)>(?(D
M6K3%G*=-;G8?/1[9^W"6KRXR$+X@G_&B*JMA \)=1=E$.8G["S@9FZMRZ*"#
MPR<"$1SA^.)9 H.\&RM$)A6FUYRW.)DRKS*9L'<:&F$X$&BJ4H52+2MHJ'%G
MK?5QOH)1*O1FQ8F4[^MV5L,I" >H^2TXBFH^'UE<XEAK09G!9)[ GN5!>OKP
MF;X5=CJK.;QJZ'2\2$ ?P!^3%DZ\"C4F.&YT>Y73BXK^K;%KO#ANVH/Q"$[M
MIJUQ59D7I'2FR4$.JU6=E[A>J2\9CM9N+)M;$2Q7,(M] @7F(+BJCIWK(O5Y
MKE8XBR"\09PO5%61C( M&\%L@C[6DB"!M7U>@@8'R^<<C)0F(DEO-..8#VE8
M;_.\396C:9^B>C0>O5^1N&%M^)\MC-,B@PFG7R/S(W^<K%8@.S(6<R?HCX"?
M3D =J[)Y8V[Z"&NB[WOI)/Q>#?P$AD-27SQXF: DX^](SAUFEZ@0IF0N7"8Y
M]$!>?[_P-BZ\\6AR7BFUM'O?68,1GVE)=%7AD5*@6% YG U5663S*"WG+=Z(
M"AUIRZS4D:QA<0830G9 3>=5LEKEH*^#R46+M. )Y$6IH"7^NCR(I@F()[[&
M-!*E#HBD?Z/U  _QWX563>:=C?2@^Q4PL +H -FL88IFLG"4 O\$NQ_=H=&U
MD@HV6;^0UQM,;P44O$VN-3V4I*L,%SV9CG-%1C\(='@NM+XD303DX"I9+W=&
M,[N5F2A3M7F9'Z'7H$AR.),N5='BZDX5VU,_?->UIU!S$V\*B$2\EK^O5$XS
M0K96[-E8Y'/ M\ !V?!W=WC"OK$NR/_QX$'T.E-Y^CSZD)RK%W#][ZT")0$>
M&SUX(*&0GPZ/?O4#"@^:<@67/%Z9D,2#6=DTY?)Y]!U^-RLK$/?FNY=Y L?\
M(WAY7>99"@WH!BA<!_L':"&\L^?ULTHEGQ[,%*JASV%S8)O=)GW7TR)LYDU?
MZ0S,MS@R/!AW<3;_Z]M/NTJ'-V&"A[=<189P"EH#: -H@;(K$5X.CYR511(M
MX!.IP'#%90:[4*L"VJK"!Q36E4K[MW"M6'P;F/)XH(F=7(Y'OXMN6]/U?0V"
M?UE).2I /VW)#H\F!X\.]I+]O4?[/&T@-5Z#O<X?3A_\X.C;:+K=W4W_7UXF
M6H<?CT(E_J8')VN4RCTVYY5*R=--E@/Z8. 4C5)Y9<T^ZZNRS5.VI6=*@?V]
M2C*ZF+SG%V AD_;#%DF]@N.9+"$Q>P=MD&@/UDU)?J&$6@OM$L=,(T=&O1]E
M"_8$R'LNDI0: 0IOW:(*02HSM X$3C1;N_V\7U)#2VJZ6(#2"O,_'AW"* ^N
M(QS,% 4%!5QP9DS<:*;F);Y>Z4?Y'FR8^U-%<D!B@S_>S\;@;'R>7R3%.4Q&
MKV,[ZO5KZYL<!_?3>P?W+<S.ZR2KQJ-W2?4)%O>O2=[V;1>Q_5@"PF;!P_8<
M-D7!V\?.X *>AMW#AUWBP_Q;'<<A[*#SLDSQ#HP(K3D^[+G;7V@5 &;[HKP"
M%;V*66)G[D.S.LKA%F5$]C%-/VCU$]#3M5<*!;A=7H<*!#48M9,6]$#2W?_9
MEJR?1Z=K>-AR/-J3$3I.ZC3Y78=LXX@_1V_R<@;OX)&+R3.+X_];67V2AIDU
M3-H&GP2%;EMM&Z.<ZZ#G*?<$QUC533*#SEW@2;"4-Y'4<EW2XLF;P43 S3B6
MY!9$91W/')F.WW4'ZX/H:,%[@SS/1<\E%#RF<PDGN.>=X]'FE^(->5(WO$#0
M.ZAL5)B^PS<8H2M-Z3;U?M\.[%OCKQV/7)?L!IUI[?EN*3Q]SIX$E)N_&P\O
M:\WRFLRXA6O>_.Y;\%(W;N$=B4\?/[8^H_1>6QF<R7<@\98M")Q?8;OC'OD
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M"KO9.B#L#VR])8U%'3&8T)23$;-\&%$8 +'N<#W"[?SG/WS%_O,?[OWGNU0
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M2CT&U?\N;_<[H7SR60/G5MT'T/VHW?F"YV=U8 .O],I"" EBX$19O#@%"/6
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MB:J9$.A"JJTL^D>C/WN8;=W'1.8I<_0H<4Y@V38&:LPFI0;.ZFV(?EYVJA)
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M70,  &-O;&PM,C R-3 U,35?;&%B+GAM;%!+ 0(4 Q0    ( *F LUH*Q(L
M70<  .-7   5              "  8X.  !C;VQL+3(P,C4P-3$U7W!R92YX
M;6Q02P$"% ,4    " "I@+-:6"H;L5@8   'H@  $@              @ $>
M%@  =&TR-3$U-30Y9#%?.&LN:'1M4$L! A0#%     @ J8"S6HRW<>?@0P
M(8@! !8              ( !IBX  '1M,C4Q-34T.60Q7V5X,3 M,2YH=&U0
52P4&      4 !0!) 0  NG(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>tm2515549d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="coll-20250515.xsd" xlink:type="simple"/>
    <context id="AsOf2025-05-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267565</identifier>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-05-15" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-05-15" id="Fact000004">0001267565</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-05-15" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-05-15" id="Fact000010">2025-05-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-05-15" id="Fact000011">COLLEGIUM PHARMACEUTICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-05-15" id="Fact000012">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-05-15" id="Fact000013">001-37372</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-05-15" id="Fact000014">03-0416362</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-05-15" id="Fact000015">100 Technology Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-05-15" id="Fact000016">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-05-15" id="Fact000017">Stoughton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-05-15" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-05-15" id="Fact000019">02072</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-05-15" id="Fact000020">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-05-15" id="Fact000021">713-3699</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="AsOf2025-05-15" id="Fact000022">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-05-15" id="Fact000023">COLL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-05-15" id="Fact000024">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="AsOf2025-05-15" id="Fact000025">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-05-15" id="Fact000026">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-05-15" id="Fact000027">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-05-15" id="Fact000028">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-05-15" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
